Ovid Therapeutics Inc. OVID
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-05-05
Chart by TradingView
1/9
Piotroski F — financial health
0.8
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2025 | FY2024 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $7.3M | $223.6M | $566,000 | $223.4M | $223.2M |
| Operating income | -$42.4M | — | -$61.9M | — | — |
| Net income | -$17.4M | — | -$26.4M | — | — |
| Operating cash flow | -$38.3M | — | -$56.0M | — | — |
| Free cash flow | -$38.3M | — | -$56.0M | — | — |
| Total assets | $150.9M | $81.7M | $92.2M | $102.7M | $118.1M |
| Total liabilities | $20.3M | $22.4M | $23.9M | $26.4M | $29.2M |
| Shareholders' equity | $130.7M | $59.3M | $68.2M | $76.3M | $88.9M |
| Ratios | |||||
| Operating margin | -585.2% | — | -10933.7% | — | — |
| Net margin | -240.1% | — | -4670.1% | — | — |
| FCF margin | -528.6% | — | -9898.8% | — | — |
| Return on assets | -11.5% | — | -28.7% | — | — |
| Return on equity | -13.3% | — | -38.7% | — | — |
| Current ratio | 8.97 | 4.93 | 5.32 | 5.66 | 5.73 |
| Revenue growth | -96.8% | 39405.3% | -99.7% | 0.1% | 0.1% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 1,320,610 | $2.9M |
| RENAISSANCE TECHNOLOGIES LLC | 1,104,300 | $2.5M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.8 (distress)
- Working capital / assets 0.438
- Retained earnings / assets -2.131
- EBIT / assets -0.281
- Equity / liabilities 6.445
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001636651 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.